Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;43 Suppl 2(Suppl 2):e70070.
doi: 10.1002/hon.70070.

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects

Emil Kumar  1 , Jessica Okosun  2
Affiliations
Review

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects

Emil Kumar et al. Hematol Oncol. 2025 Jun.

Abstract

Significant strides have been made in the treatment of follicular lymphoma, leading to improvements in long-term patient outcomes. However, the disease's heterogeneity presents challenges in selecting the optimal therapy at each stage of treatment. The expanding array of therapeutic options introduces new complexities, including making the right initial choice, sequencing treatments effectively, and redefining treatment goals. As the landscape evolves, there is a growing need to shift toward precision-based treatment decisions, potentially guided by underlying disease biology. Here, we explore recent advancements in both upfront and relapsed/refractory treatment strategies, addressing considerations in therapy selection, and the current progress toward precision approaches with its potential to enhance decision-making.

Keywords: CAR‐T; biomarkers; bispecific antibodies; follicular lymphoma; immunotherapy; minimal residual disease.

PubMed Disclaimer

Conflict of interest statement

J.O. has received research funding from AstraZeneca, BeiGene and Genmab and reports consultancy for AstraZeneca, Genmab and Incyte Corporation.

Similar articles

See all similar articles

References

    1. Kumar E., Pickard L., and Okosun J., “Pathogenesis of Follicular Lymphoma: Genetics to the Microenvironment to Clinical Translation,” British Journal of Haematology 194, no. 5 (2021): 810–821, 10.1111/bjh.17383. - DOI - PubMed
    1. Ardeshna K. M., Qian W., Smith P., et al., “Rituximab Versus a Watch‐and‐Wait Approach in Patients With Advanced‐Stage, Asymptomatic, Non‐Bulky Follicular Lymphoma: An Open‐Label Randomised Phase 3 Trial,” Lancet Oncology 15, no. 4 (2014): 424–435, 10.1016/s1470-2045(14)70027-0. - DOI - PubMed
    1. Northend M., Wilson W., Clifton‐Hadley L., et al., “Long Term Follow‐Up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients With Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment Without Detrimental Impact Following Next Line of Therapy,” supplement, Blood 140, no. S1 (2022): 1456–1458, 10.1182/blood-2022-156790. - DOI
    1. Kahl B. S., Hong F., Williams M. E., et al., “Rituximab Extended Schedule or Re‐treatment Trial for Low‐Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol e4402,” Journal of Clinical Oncology 32, no. 28 (2014): 3096–3102, 10.1200/jco.2014.56.5853. - DOI - PMC - PubMed
    1. Kahl B. S., Jegede O. A., Peterson C., et al., “Long‐Term Follow‐Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low‐Tumor Burden Follicular Lymphoma,” Journal of Clinical Oncology 42, no. 7 (2024): 774–778, 10.1200/jco.23.01912. - DOI - PMC - PubMed